RE:RE:RE:Nash partnership deal It would be interesting to know if GSK even looked at Egrifta before deciding to move ahead with Arrowhead. That is a very sweet deal in this NASH environment and one has to think the science behind their drug is pretty impressive. To get terms that good, there must have been other Big Pharmas competing for the rights to Arrowhead's drug. Maybe one of those will see Egrifta as a fallback option but I am guessing the chances of that are low.
longterm56 wrote: Whoa!!! Please ... someone with a good contact at THTX ... make sure they are aware of this!!!! $120M upfront for a drug not yet in Phase 2???? This should immediately increase THTX's market cap by > $100M .... immediately!!!
-LT
jeffm34 wrote: Financial Terms
Under the terms of the agreement, Arrowhead will receive an upfront payment of $120 million and is eligible for additional payments of $30 million at the start of Phase 2 and $100 million upon achieving a successful Phase 2 trial readout and the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to Arrowhead of up to $190 million at first commercial sale, and up to $590 million in sales-related milestone payments. Arrowhead is further eligible to receive tiered royalties on net product sales.
GSK will receive an exclusive license to develop and commercialize ARO-HSD in all territories except Greater China, which will be retained by Arrowhead. GSK will be wholly responsible for further clinical development and commercialization, outside of Greater China